Pfizer Inc. (PFE)
| Previous close | 36.53 |
| Open | 36.78 |
| Bid | 37.24 x 1800 |
| Ask | 37.29 x 1000 |
| Day's range | 36.75 - 37.26 |
| 52-week range | 26.45 - 39.84 |
| Volume | 25,080,500 |
| Avg. volume | 33,594,268 |
| Market cap | 206.939B |
| Beta (5Y monthly) | 0.64 |
| PE ratio (TTM) | 24.21 |
| EPS (TTM) | 1.54 |
| Earnings date | 26 Jan 2021 - 01 Feb 2021 |
| Forward dividend & yield | 1.52 (4.08%) |
| Ex-dividend date | 05 Nov 2020 |
| 1y target est | 41.78 |
- Editor's pickYahoo Finance
The US could face an 'apocalypse’ by Christmas as COVID-19 cases surge: Dr.
As COVID-19 hospitalizations surpass 90,000 for the first time, a record for the seventeenth day in a row, Dr. Andre Campbell, a trauma surgeon at Zuckerberg San Francisco General Hospital, warns the U.S. could be facing an “apocalypse” next month.
- Yahoo Finance UK
UK could become first Western country to approve a COVID-19 vaccine
On Friday, the government wrote to the Medicines and Healthcare Products Regulatory Agency, asking it to review the Astrazeneca-Oxford University vaccine.
- Motley Fool
Pfizer's Vaccine Candidate Is Effective -- But It Has Issues
As the excitement over Pfizer (NYSE: PFE) and BioNTech's (NASDAQ: BNTX) vaccine announcement ebbs, some harsh realities have started to set in. The vaccine candidate -- while a marvelous feat of science -- has some hurdles to overcome if it's going to fulfill the promise of helping end the global pandemic. Let's look at a few issues the potential Pfizer vaccine will have to overcome to reward shareholders and save lives.
